



Immobilized Anti-Fusion glycoprotein F0 Antibody, Human IgG1 (D25) at 5 µg/mL (100 µL/well) can bind Biotinylated Human respiratory syncytial virus A (strain A2) Pre-F0, His,Avitag (Cat. No. RSF-V82E7) with a linear range of 0.1-8 ng/mL (QC tested).



Immobilized Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) at 5 µg/mL (100 µL/well) can bind Biotinylated Human respiratory syncytial virus A (strain A2) Pre-F0, His,Avitag (Cat. No. RSF-V82E7) with a linear range of 0.2-16 ng/mL (QC tested).



Immobilized Recombinant Mouse Anti-RSV F Antibody (5C4) at 5 µg/mL (100 µL/well) can bind Biotinylated Human respiratory syncytial virus A (strain A2) Pre-F0, His,Avitag (Cat. No. RSF-V82E7) with a linear range of 0.2-16 ng/mL (QC tested).

Background

Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation.

Clinical and Translational Updates

Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.